Amgen reported strong full-year and Q4 results with significant revenue and EPS growth, underpinned by robust demand for key products and an expansive R&D pipeline. While there are concerns regarding the Aranesp Phase III study and Sensipar's new indication, management's optimistic guidance and strategic investments in growth areas are likely to reassure investors in the short term.

[1]